4.5 Article

Imaging of glia activation in people with primary lateral sclerosis

期刊

NEUROIMAGE-CLINICAL
卷 17, 期 -, 页码 347-353

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.nicl.2017.10.024

关键词

Diffusion; PET; TSPO; Primary lateral sclerosis; Amyotrophic lateral sclerosis; [C-11]-PBR28

资金

  1. Spastic Paraplegia Foundation
  2. NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB014894] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS083715] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Background: Glia activation is thought to contribute to neuronal damage in several neurodegenerative diseases based on preclinical and human post-mortem studies, but its role in primary lateral sclerosis (PLS) is unknown. Objectives: To localize and measure glia activation in people with PLS compared to healthy controls (HC). Methods: Ten participants with PLS and ten age-matched HCs underwent simultaneous magnetic resonance (MR) and proton emission tomography (PET). The radiotracer [C-11]-PBR28 was used to obtain PET-based measures of 18 kDa translocator protein (TSPO) expression, a marker of activated glial cells. MR techniques included a structural sequence to measure cortical thickness and diffusion tensor imaging (DTI) to assess white matter integrity. Results: PET data showed increased [C-11]-PBR28 uptake in anatomically-relevant motor regions which co-localized with areas of regional gray matter atrophy and decreased subcortical fractional anisotropy. Conclusions: This study supports a link between glia activation and neuronal degeneration in PLS, and suggests that these disease mechanisms can be measured in vivo in PLS. Future studies are needed to determine the longitudinal changes of these imaging measures and to clarify if MR-PET with [C-11]-PBR28 can be used as a biomarker for drug development in the context of clinical trials for PLS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据